Cirius Therapeutics is a clinical-stage pharmaceutical company focused on the development of innovative therapies for the treatment of liver and metabolic diseases. Cirius is developing MSDC-0602K, a novel, once-daily, oral small molecule for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis. MSDC-0602K is designed to selectively modulate the mitochondrial pyruvate carrier (MPC), which mediates at the cellular level the effects of overnutrition, a major cause of NASH and other metabolic disorders.
Cirius was founded based on the discovery of the modulatory effect of thiazolidinediones on the mitochondrial pyruvate carrier (MPC), and the resulting improvements in cellular glucose metabolism, in which Cirius’ co-founder Jerry Colca, Ph.D., played a key role.
The company is conducting a Phase 2b clinical trial of MSDC-0602K, which has been fully enrolled with 402 patients diagnosed with NASH with fibrosis. Cirius expects to report final data from this clinical trial in the second half of 2019.